The global Heterozygous Familial Hypercholesterolemia (HEFH) Management Market is projected to be valued at US$ 15.11 billion in the fiscal year 2023, up from US$ 13.2 billion in 2022. This growth underscores a significant rise in awareness and diagnosis of the condition. The market is expected to grow at a robust compound annual growth rate (CAGR) of 14.5% from 2023 to 2033, ultimately reaching an estimated value of US$ 58.54 billion by the end of the forecast period.
Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of low-density lipoprotein (LDL) cholesterol, commonly referred to as “bad cholesterol,” present from birth. Unlike lifestyle-related conditions, FH is caused by specific DNA alterations that are inherited from one generation to the next. Understanding that FH is not a result of dietary habits or physical inactivity is crucial for proper management and treatment of this condition.
Key Market Insights:
- Projected Market Value for 2023: US$ 15.11 billion
- Market Value in 2022: US$ 13.2 billion
- Anticipated CAGR (2023-2033): 14.5%
- Projected Market Value by 2033: US$ 58.54 billion
The increase in market value is driven by several factors, including advancements in treatment options, increased genetic testing, and a growing emphasis on early diagnosis and management of familial hypercholesterolemia. As awareness surrounding FH continues to rise, healthcare providers are better equipped to offer tailored treatment strategies, thereby improving patient outcomes.
The HEFH management market is positioned for significant growth as ongoing research and development efforts aim to enhance therapeutic options for patients living with this genetic disorder.
The heart can be damaged over time, resulting in heart disease. If this occurs, one of the primary symptoms is chest discomfort known as angina. This could result in a heart attack or even stroke if not treated. Thus, this disease needs to be treated at the earliest, and such reasons are why there is a surge in demand within the Heterozygous Familial Hypercholesterolemia (HEFH) management market globally.
Increasing Treatment Options and Innovations to augment Treatment Incidences
During the forecast period, the European market for Heterozygous Familial Hypercholesterolemia (HEFH) management is expected to garner a steady CAGR of 14%. But at the time, the European market for the management of heterozygous familial hypercholesterolemia (HEFH) is expected to witness this market gain of 31% in 2023. Expanding research and innovations by the key players and various projects being approved for the management of Heterozygous Familial Hypercholesterolemia and increasing authorizations of the clinical trials by some prominent companies in the region are propelling the growth.
Verve Therapeutics, Inc., a clinical-stage biopharmaceutical company that is developing single-course gene editing drugs to treat cardiovascular disease, declared in 2022 that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) had approved its Clinical Trial Authorization (CTA) application for VERVE-101 as a prospective treatment for people with heterozygous familial hypercholesterolemia (HeFH). HeFH is a common hereditary variant of atherosclerotic cardiovascular disease (ASCVD) that can be fatal and is characterized by abnormally high blood levels of the disease-causing lipid LDL-cholesterol (LDL-C). Such developments are expected to accelerate the growth in the market from 2023 to 2033.
Competitive Landscape
Some of the prominent players in the global market for heterozygous familial hypercholesterolemia (HEFH) management are:
- Sanofi SA
- Amgen Inc.
- Novartis International AG
- AdooQ Bioscience
- Thermo Fisher Scientific
- Universal Biologicals
- Selleck Chemicals
- Madrigal Pharmaceuticals
- ShangHai Caerulum Pharma Discovery Co., Ltd.
- Wuhan Biocar Pharmacy
Some of the prominent developments of the key players in the market are:
- Novartis announced in 2021 that the US Food and Drug Administration (FDA) had approved Leqvio® (inclisiran), the world’s first and only small interfering RNA (siRNA) medication to reduce low-density lipoprotein cholesterol (known colloquially as bad cholesterol or LDL-C) with 2 doses per year, after an initial dosage and one at three months. Leqvio is a ground-breaking strategy to reduce LDL-C and opens up new avenues as to how healthcare systems might influence cardiovascular disease, which is the most important public health issue of our day. They now have the chance to offer this first-ever authorized LDL-C-lowering siRNA-based treatment to combat ASCVD at scale throughout the United States in collaboration with partners.
- In the US, Leqvio is prescribed to people with symptomatic atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) who need further LDL-C reduction in combination with diet and maximally tolerated statin medication. In ongoing clinical studies, the impact of Leqvio on cardiovascular mortality and morbidity is being investigated.
Key Companies Profiled
Sanofi SA; Amgen Inc.; Novartis International AG; AdooQ Bioscience; Thermo Fisher Scientific; Universal Biologicals; Selleck Chemicals; Madrigal Pharmaceuticals; Shanghai Caerulum Pharma Discovery Co., Ltd.; Wuhan Biocar Pharmacy
Key Segments Covered in the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market Report
By Product Type:
- Gemcabene Calcium
- MGL-3196
- ST-103
- Others
By Application:
- Hospitals
- Medical Centers
- Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
